NCT05043077View on ClinicalTrials.gov

Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening

PHASE4CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

January 20, 2023

Study Completion Date

January 23, 2023

Conditions
Retinopathy of Prematurity
Interventions
DRUG

Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%

1 drop (6.5 μL) for 3 doses with 5-minute intervals

DRUG

Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%

1 drop (28-34 μL) for 3 doses with 5-minute intervals

Trial Locations (1)

56429

Papageorgiou General Hospital, Thessaloniki

All Listed Sponsors
collaborator

National and Kapodistrian University of Athens

OTHER

lead

Aristotle University Of Thessaloniki

OTHER

NCT05043077 - Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening | Biotech Hunter | Biotech Hunter